{"id":39884,"date":"2026-07-21T01:02:00","date_gmt":"2026-07-20T23:02:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=3d951a390c00568548f9278a9d8f232f"},"modified":"2026-07-21T01:02:00","modified_gmt":"2026-07-20T23:02:00","slug":"trilink-biotechnologies-further-strengthens-global-ip-position-with-newly-issued-patent-in-china-for-cleancap-capping-technology","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=39884","title":{"rendered":"TriLink BioTechnologies\u00ae Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap\u00ae Capping Technology"},"content":{"rendered":"

\nTriLink's Complete Portfolio of CleanCap\u00ae Analogs are Patented in Major Jurisdictions Globally; TriLink is the Sole Authorized Manufacturer of CleanCap\u00ae Capping Analogs<\/i><\/p><\/a><\/a>

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink\u00ae), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules. The new patent covers TriLink's full suite of CleanCap\u00ae capping analogs, including its latest M6 analog. CleanCap technology is a critical component of the production of synthetic mRNA as drug developers and researchers strive to maximize the impact of mRNA-based therapeutics and vaccines.<\/p>

\nThe allowed claims are directed to co-transcriptional RNA synthesis methods utilizing either trimer or tetramer capping structures.<\/p>

\nThis new patent reinforces the global strength of TriLink's intellectual property portfolio in one of the world's most strategically important markets. CleanCap\u00ae technology is patented across major world markets in addition to China, including the United States, the European Union, Australia, Japan, Korea, Hong Kong, and Canada.<\/p>

\n\"We are committed to defending our intellectual property rights, and this new patent represents an important tool in support of those efforts,\" said Bernd Brust, Chief Executive Officer of Maravai LifeSciences. \"Maintaining strong intellectual property coverage in every major jurisdiction is central to our strategy. We look forward to deepening our presence in this important market and bringing the gold standard in mRNA capping technology to the researchers and drug developers who are advancing the next generation of RNA-based medicines.\"<\/p>

\n\"CleanCap\u00ae offers significant advantages for mRNA programs,\" said Chanfeng Zhao, Chief Scientific Officer of TriLink BioTechnologies. \"This patent reflects the depth of innovation our team has brought to mRNA manufacturing.\"<\/p>

\nThe technology covered by the patent enables the co-transcriptional production of mRNAs containing the major natural cap structures found in humans, a significant improvement over legacy capping methods such as enzymatic capping and ARCA. CleanCap\u00ae technology has been used in commercially approved COVID-19 mRNA and saRNA vaccines and underpins drug development programs across mRNA therapeutics, oncology, infectious diseases, rare diseases, and cell and gene therapies.<\/p>

\nTo learn more about TriLink's products and services, visit trilinkbiotech.com.<\/p>

\nAbout TriLink BioTechnologies<\/b><\/p>

\nTriLink BioTechnologies, part of Maravai LifeSciences, is a global leader in nucleic acid technologies and manufacturing solutions for RNA therapeutics, vaccines, gene editing, and diagnostics. The company's portfolio includes modified nucleotides, mRNA products, proprietary technologies such as CleanCap\u00ae capping analogs and ModTail\u2122 technology, and a growing portfolio of high-performance enzymes marketed under the Alphazyme brand. Supported by robust GMP manufacturing capabilities, TriLink enables customers from early-stage research through commercial production.<\/p>

\nFor more information, visit trilinkbiotech.com.<\/p>

\nAbout Maravai LifeSciences<\/b><\/p>

\nMaravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.<\/p>

\nFor more information about Maravai LifeSciences, visit www.maravai.com<\/a>.<\/p>

\nForward-looking statements<\/b><\/p>

\nThis press release contains, and Maravai's officers and representatives may from time-to-time make, \"forward-looking statements\" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements regarding the expected benefits associated with using CleanCap\u00ae technology, the expected impact of mRNA vaccines and therapeutics; Maravai's future business capabilities; growth opportunities, including inorganic growth; and future innovations, constitute forward-looking statements and are identified by words like \"promise,\" \"believe,\" \"expect,\" \"see,\" \"project,\" \"may,\" \"will,\" \"should,\" \"seek,\" \"anticipate,\" or \"could\" and similar expressions.<\/p> Contacts<\/b>

\nInvestor Contact:\nDeb Hart\nMaravai LifeSciences\n+1 858-988-5917\nir@maravai.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

TriLink’s Complete Portfolio of CleanCap\u00ae Analogs are Patented in Major Jurisdictions Globally; TriLink is the Sole Authorized Manufacturer of CleanCap\u00ae Capping AnalogsSAN DIEGO–(BUSINESS WIRE)–TriLink BioTechnologies, LLC (TriLink\u00ae), a Maravai Life…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-39884","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/39884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39884"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/39884\/revisions"}],"predecessor-version":[{"id":39885,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/39884\/revisions\/39885"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}